U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C17H23N5O2
Molecular Weight 329.3968
Optical Activity UNSPECIFIED
Defined Stereocenters 2 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SUNEPITRON

SMILES

O=C1CCC(=O)N1C[C@H]2CC[C@H]3CN(CCN3C2)C4=NC=CC=N4

InChI

InChIKey=UXWBIYCPUVWKHP-KBPBESRZSA-N
InChI=1S/C17H23N5O2/c23-15-4-5-16(24)22(15)11-13-2-3-14-12-21(9-8-20(14)10-13)17-18-6-1-7-19-17/h1,6-7,13-14H,2-5,8-12H2/t13-,14-/m0/s1

HIDE SMILES / InChI
Molecular Formula C17H23N5O2
Molecular Weight 329.3968
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including: http://en.pharmacodia.com/web/drug/1_8718.html

Sunepitron (CP-93,393) is an anxiolytic drug with highly selective serotonin 5-hydroxytryptamine 1A autoreceptor agonist, alpha2-adrenergic antagonist, and dopamine D2 agonist properties. Sunepitron hydrochloride had been in Phase III clinical trials by Pfizer for the treatment of anxiety disorder and depression. However, this research has been discontinued.

CNS Activity

Originator

Approval Year

Unknown
149124
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2849
Agonist
2752
 92.0 nM [Ki]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase III
665
Unknown

Approved Use

Unknown
Primary
Withdrawn
Unknown

Approved Use

Unknown
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.02 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9571226/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUNEPITRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
10.92 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9571226/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUNEPITRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
2.36 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9571226/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUNEPITRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
87.33 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9571226/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUNEPITRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.9 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9571226/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUNEPITRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
4.1 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/9571226/
5 mg single, oral
dose: 5 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
SUNEPITRON plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
5 mg single, oral
Dose: 5 mg
Route: oral
Route: single
Dose: 5 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/9571226/
healthy
Health Status: healthy
Sex: M
Food Status: UNKNOWN
Sources:
https://pubmed.ncbi.nlm.nih.gov/9571226/
Sources:
https://pubmed.ncbi.nlm.nih.gov/9571226/
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1388

OverviewOther

Other InhibitorOther SubstrateOther Inducer
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP2D6
1388
 major
Sourcing

Sourcing

Vendor/AggregatorIDURL
Axon MedChem
1519
https://www.axonmedchem.com/product/1519
BOC Sciences
148408-65-5
http://www.bocsci.com/description.asp?cas=148408-65-5
Compound Cloud
183092
Compound Cloud
6918176
eMolecules
110068823
https://orderbb.emolecules.com/search/#?query=110068823
eMolecules
271446115
https://orderbb.emolecules.com/search/#?query=271446115
eMolecules
301236505
https://orderbb.emolecules.com/search/#?query=301236505
eMolecules
301236761
https://orderbb.emolecules.com/search/#?query=301236761
eMolecules
50580280
https://orderbb.emolecules.com/search/#?query=50580280
mcule
MCULE-1128895085
https://mcule.com/MCULE-1128895085/
mcule
MCULE-2945972636
https://mcule.com/MCULE-2945972636/
MolPort
MolPort-042-665-705
https://www.molport.com/shop/molecule-link/MolPort-042-665-705
MuseChem
I009649
https://www.musechem.com/product/I009649.html
Tetrahedron
TS77820
http://www.thsci.com/search.do?q=TS77820
PubMed

PubMed

TitleDatePubMed
Psychopharmacology of depression in the next millennium.
1999-07
Assay and purity evaluation of sunepitron hydrochloride by reversed-phase liquid chromatography using a reference standard composite.
1998-11
Metabolism and excretion of a new anxiolytic drug candidate, CP-93, 393, in healthy male volunteers.
1998-05
Metabolism and excretion of a new antianxiety drug candidate, CP-93,393, in cynomolgus monkeys: identification of the novel pyrimidine ring cleaved metabolites.
1997-12
Patents

Patents

US5122525
2
US7678363
2

Sample Use Guides

In Vivo Use Guide
The excretion, biotransformation, and pharmacokinetics of Sunepitron (CP-93,393) were investigated in six healthy male volunteers after oral administration of a 5-mg dose of [14C]CP-93,393.
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Wed Apr 02 09:08:43 GMT 2025
Edited
by admin
on Wed Apr 02 09:08:43 GMT 2025
Record UNII
2GT50C8U60
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CP 93393
Preferred Name English
SUNEPITRON
INN  
INN  
Official Name English
sunepitron [INN]
Common Name English
CP-93,393
Code English
2,5-PYRROLIDINEDIONE, 1-(((7S,9AS)-OCTAHYDRO-2-(2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)-
Common Name English
CP-93393
Code English
Classification Tree Code System Code
NCI_THESAURUS C47794
Created by admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
NCI_THESAURUS C29713
Created by admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
Code System Code Type Description
WIKIPEDIA
Sunepitron
Created by admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
PRIMARY
EPA CompTox
DTXSID801336204
Created by admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
PRIMARY
CAS
131831-03-3
Created by admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
PRIMARY
SMS_ID
100000082983
Created by admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
PRIMARY
PUBCHEM
183092
Created by admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
PRIMARY
FDA UNII
2GT50C8U60
Created by admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
PRIMARY
ChEMBL
CHEMBL2111058
Created by admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
PRIMARY
INN
7670
Created by admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
PRIMARY
EVMPD
SUB10774MIG
Created by admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
PRIMARY
NCI_THESAURUS
C152473
Created by admin on Wed Apr 02 09:08:43 GMT 2025 , Edited by admin on Wed Apr 02 09:08:43 GMT 2025
PRIMARY
Related Record Type Details
5-HYDROXYTRYPTAMINE RECEPTOR 1A
TARGET -> AGONIST
SELECTIVE
Structure of SUNEPITRON HYDROCHLORIDE
SALT/SOLVATE -> PARENT
CYTOCHROME P450 2D6
METABOLIC ENZYME -> SUBSTRATE
MAJOR
D(2) DOPAMINE RECEPTOR
TARGET -> AGONIST
Related Record Type Details
Structure of .BETA.-D-GLUCOPYRANOSIDURONIC ACID, 2-((7S,9AS)-7-((2,5-DIOXO-1-PYRROLIDINYL)METHYL)OCTAHYDRO-2H-PYRIDO(1,2-A)PYRAZIN-2-YL)-5-PYRIMIDINYL
METABOLITE -> PARENT
IN EXTENSIVE METABOLIZERS
URINE
Structure of 4-((((7R,9AS)-OCTAHYDRO-2-(2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)AMINO)-4-OXOBUTANOIC ACID
METABOLITE -> PARENT
IN EXTENSIVE METABOLIZERS
URINE
Structure of .BETA.-D-GLUCOPYRANOSIDURONIC ACID, 2-((7S,9AS)-7-((2,5-DIOXO-1-PYRROLIDINYL)METHYL)OCTAHYDRO-2H-PYRIDO(1,2-A)PYRAZIN-2-YL)-5-PYRIMIDINYL
METABOLITE -> PARENT
IN POOR METABOLIZERS
PLASMA
Structure of 4-((((7R,9AS)-OCTAHYDRO-2-(5-HYDROXY-2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)AMINO)-4-OXOBUTANOIC ACID
METABOLITE -> PARENT
IN POOR METABOLIZERS
FECAL
Structure of (7S,9AS)-7-((2,5-DIOXO-1-PYRROLIDINYL)METHYL)OCTAHYDRO-2H-PYRIDO(1,2-A)PYRAZINE-2-CARBOXIMIDAMIDE
METABOLITE -> PARENT
IN EXTENSIVE METABOLIZERS
PLASMA
Structure of 4-((((7R,9AS)-OCTAHYDRO-2-(2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)AMINO)-4-OXOBUTANOIC ACID
METABOLITE -> PARENT
IN POOR METABOLIZERS
URINE
Structure of (7S,9AS)-7-((2,5-DIOXO-1-PYRROLIDINYL)METHYL)OCTAHYDRO-2H-PYRIDO(1,2-A)PYRAZINE-2-CARBOXIMIDAMIDE
METABOLITE -> PARENT
IN EXTENSIVE METABOLIZERS
FECAL
Structure of (7S,9AS)-7-((2,5-DIOXO-1-PYRROLIDINYL)METHYL)OCTAHYDRO-2H-PYRIDO(1,2-A)PYRAZINE-2-CARBOXIMIDAMIDE
METABOLITE -> PARENT
IN POOR METABOLIZERS
URINE
Structure of 4-((((7R,9AS)-OCTAHYDRO-2-(2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)AMINO)-4-OXOBUTANOIC ACID
METABOLITE -> PARENT
IN POOR METABOLIZERS
PLASMA
Structure of 4-((((7R,9AS)-OCTAHYDRO-2-(5-HYDROXY-2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)AMINO)-4-OXOBUTANOIC ACID
METABOLITE -> PARENT
IN EXTENSIVE METABOLIZERS
FECAL
Structure of 4-((((7R,9AS)-OCTAHYDRO-2-(5-HYDROXY-2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)AMINO)-4-OXOBUTANOIC ACID
METABOLITE -> PARENT
IN EXTENSIVE METABOLIZERS
URINE
Structure of 2-HYDROXY-4-((((7R,9AS)-OCTAHYDRO-2-(5-HYDROXY-2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)AMINO)-4-OXOBUTANOIC ACID
METABOLITE -> PARENT
IN EXTENSIVE METABOLIZERS
URINE
Structure of 2-HYDROXY-4-((((7R,9AS)-OCTAHYDRO-2-(5-HYDROXY-2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)AMINO)-4-OXOBUTANOIC ACID
METABOLITE -> PARENT
IN EXTENSIVE METABOLIZERS
URINE
Structure of (7S,9AS)-7-((2,5-DIOXO-1-PYRROLIDINYL)METHYL)OCTAHYDRO-2H-PYRIDO(1,2-A)PYRAZINE-2-CARBOXIMIDAMIDE
METABOLITE -> PARENT
IN EXTENSIVE METABOLIZERS
URINE
Structure of 1-(((7S,9AS)-OCTAHYDRO-2-(5-(SULFOOXY)-2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)-2,5-PYRROLIDINEDIONE
METABOLITE -> PARENT
IN POOR METABOLIZERS
PLASMA
Structure of .BETA.-D-GLUCOPYRANOSIDURONIC ACID, 2-((7R,9AS)-7-(((3-CARBOXY-1-OXOPROPYL)AMINO)METHYL)OCTAHYDRO-2H-PYRIDO(1,2-A)PYRAZIN-2-YL)-5-PYRIMIDINYL
METABOLITE -> PARENT
PLASMA
Structure of (7S,9AS)-7-((2,5-DIOXO-1-PYRROLIDINYL)METHYL)OCTAHYDRO-2H-PYRIDO(1,2-A)PYRAZINE-2-CARBOXIMIDAMIDE
METABOLITE -> PARENT
IN POOR METABOLIZERS
FECAL
Structure of 1-(((7S,9AS)-OCTAHYDRO-2-(5-(SULFOOXY)-2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)-2,5-PYRROLIDINEDIONE
METABOLITE -> PARENT
IN EXTENSIVE METABOLIZERS
PLASMA
Structure of 4-((((7R,9AS)-OCTAHYDRO-2-(5-HYDROXY-2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)AMINO)-4-OXOBUTANOIC ACID
METABOLITE -> PARENT
IN POOR METABOLIZERS
URINE
Structure of (7S,9AS)-7-((2,5-DIOXO-1-PYRROLIDINYL)METHYL)OCTAHYDRO-2H-PYRIDO(1,2-A)PYRAZINE-2-CARBOXIMIDAMIDE
METABOLITE -> PARENT
IN POOR METABOLIZERS
PLASMA
Structure of 1-(((7S,9AS)-OCTAHYDRO-2-(5-(SULFOOXY)-2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)-2,5-PYRROLIDINEDIONE
METABOLITE -> PARENT
IN EXTENSIVE METABOLIZERS
URINE
Structure of 4-((((7R,9AS)-OCTAHYDRO-2-(2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)AMINO)-4-OXOBUTANOIC ACID
METABOLITE -> PARENT
IN EXTENSIVE METABOLIZERS
PLASMA
Structure of 1-(((7S,9AS)-OCTAHYDRO-2-(5-(SULFOOXY)-2-PYRIMIDINYL)-2H-PYRIDO(1,2-A)PYRAZIN-7-YL)METHYL)-2,5-PYRROLIDINEDIONE
METABOLITE -> PARENT
IN POOR METABOLIZERS
URINE
Structure of .BETA.-D-GLUCOPYRANOSIDURONIC ACID, 2-((7S,9AS)-7-((2,5-DIOXO-1-PYRROLIDINYL)METHYL)OCTAHYDRO-2H-PYRIDO(1,2-A)PYRAZIN-2-YL)-5-PYRIMIDINYL
METABOLITE -> PARENT
IN EXTENSIVE METABOLIZERS
URINE
Related Record Type Details
Structure of SUNEPITRON
ACTIVE MOIETY
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966